BioNTech SE (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial in patients with metastatic squamous non-small cell lung cancer whose disease had progressed after prior immunotherapy and chemotherapy. Reuters said gotistobart nearly doubled survival compared with standard-of-care chemotherapy, strengthening the case for the drug as a potential chemotherapy-free treatment in a population with significant unmet need.
The result builds on earlier Stage 1 data, where gotistobart reduced the risk of death by 54% versus docetaxel, with a hazard ratio of 0.46. Median overall survival was not yet reached for gotistobart versus 9.95 months for docetaxel, while the 12-month progression-free survival rate was 25.2% versus 0%. BioNTech is now awaiting the pivotal Stage 2 readout, making the latest result important not only for the drug's approval prospects but also for the credibility of BioNTech's broader transition from a COVID-vaccine company toward a multi-product oncology business.
The strongest bullish argument is that gotistobart now has repeated evidence of a meaningful survival advantage in a difficult-to-treat lung-cancer population. The earlier Stage 1 dataset showed 55.6% of patients alive in the gotistobart arm versus 23.8% with docetaxel, alongside a 54% reduction in the risk of death. The latest Phase 3 update reinforces that signal rather than introducing an entirely new hypothesis. If the pivotal Stage 2 data confirm the benefit, BioNTech SE (NASDAQ:BNTX) could have a differentiated therapy capable of competing on survival rather than simply response rates, potentially supporting meaningful pricing power and a commercially attractive oncology franchise.
The result also strengthens BioNTech's broader oncology strategy because gotistobart is one piece of a much larger pipeline rather than a standalone bet. BioNTech says it has 14 ongoing pivotal trials and more than 10 novel combination programs, while its lung-cancer strategy spans more than 16 ongoing clinical trials and five Phase 3 programs. Gotistobart's success therefore provides validation for the company's immuno-oncology capabilities, while other ****** ets such as pumitamig and antibody-drug conjugates advance toward additional indications. BioNTech has identified 17+ late-stage or pivotal readouts through 2030+, creating the possibility that a successful gotistobart launch becomes the first major commercial proof point in its planned transition to a multi-product oncology company.

#stage #survival

Wall Street is looking beyond this week's Federal Reserve interest-rate decision to a potentially bigger market-moving signal: the Fed's latest dot plot and what it says about the path for rates after an expected quarter-point hike.
Fed Chair Kevin Warsh faces a pivotal test of his inflation-fighting credibility as policymakers confront hotter prices, rising energy costs, and mounting bets on further rate increases.
A hike on Sept. 16 would be the Fed's first increase since July 2023, but investors may care even more what the dot plot signals for additional hikes and how aggressively Warsh intends to push rates to bring inflation back to the central bank's 2% goal.
Note that a rate hike is certain to draw highly vocal criticism from President Donald Trump and his allies, who have been campaigning for a drastic slash to 1% or less for years.
Remember, the Fed doesn't traditionally pull the "one and done" game when it comes to increasing the benchmark short-term interest rate. The Federal Open Market Committee reset of the Federal Funds Rate usually lands in a package of at least two, if not more.

#rate

BioNTech SE (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial in patients with metastatic squamous non-small cell lung cancer whose disease had progressed after prior immunotherapy and chemotherapy. Reuters said gotistobart nearly doubled survival compared with standard-of-care chemotherapy, strengthening the case for the drug as a potential chemotherapy-free treatment in a population with significant unmet need.
The result builds on earlier Stage 1 data, where gotistobart reduced the risk of death by 54% versus docetaxel, with a hazard ratio of 0.46. Median overall survival was not yet reached for gotistobart versus 9.95 months for docetaxel, while the 12-month progression-free survival rate was 25.2% versus 0%. BioNTech is now awaiting the pivotal Stage 2 readout, making the latest result important not only for the drug's approval prospects but also for the credibility of BioNTech's broader transition from a COVID-vaccine company toward a multi-product oncology business.
The strongest bullish argument is that gotistobart now has repeated evidence of a meaningful survival advantage in a difficult-to-treat lung-cancer population. The earlier Stage 1 dataset showed 55.6% of patients alive in the gotistobart arm versus 23.8% with docetaxel, alongside a 54% reduction in the risk of death. The latest Phase 3 update reinforces that signal rather than introducing an entirely new hypothesis. If the pivotal Stage 2 data confirm the benefit, BioNTech SE (NASDAQ:BNTX) could have a differentiated therapy capable of competing on survival rather than simply response rates, potentially supporting meaningful pricing power and a commercially attractive oncology franchise.
The result also strengthens BioNTech's broader oncology strategy because gotistobart is one piece of a much larger pipeline rather than a standalone bet. BioNTech says it has 14 ongoing pivotal trials and more than 10 novel combination programs, while its lung-cancer strategy spans more than 16 ongoing clinical trials and five Phase 3 programs. Gotistobart's success therefore provides validation for the company's immuno-oncology capabilities, while other ***** ets such as pumitamig and antibody-drug conjugates advance toward additional indications. BioNTech has identified 17+ late-stage or pivotal readouts through 2030+, creating the possibility that a successful gotistobart launch becomes the first major commercial proof point in its planned transition to a multi-product oncology company.

#biontech #survival

Energy Transfer LP (NYSE:ET) is set to move the primary listing of its common and Series I preferred units from the New York Stock Exchange to the Texas Stock Exchange in early October, making it the first major company to make such a switch from the NYSE to the newly established Dallas exchange. Reuters said the companies moving to TXSE, including Energy Transfer and related energy businesses, represent nearly $100 billion in combined market value, giving the fledgling exchange an important early credibility boost.
For Energy Transfer LP (NYSE:ET), however, the more important question is whether the move can eventually translate into better investor visibility or valuation rather than simply giving the company a stronger Texas identity. WSJ reported that Energy Transfer is worth roughly $75 billion and that Executive Chairman Kelcy Warren is a major backer of TXSE, owning about 30% of its parent company. That relationship makes the listing particularly significant, but it also means investors may scrutinize whether the decision creates a tangible benefit for Energy Transfer unitholders rather than primarily helping establish the new exchange.
The strongest bull argument is that Energy Transfer LP (NYSE:ET) is positioning itself ahead of a potentially important shift in the U.S. energy infrastructure market. TXSE is backed by major financial institutions including BlackRock, Citadel Securities, and Charles Schwab, and winning a roughly $75 billion company gives the exchange substantially more credibility with institutional investors. If TXSE attracts additional large energy companies, Energy Transfer could benefit from becoming one of the exchange's anchor names and gaining greater visibility among investors already focused on Texas-based energy infrastructure.
More importantly, the listing decision fits the underlying environment in which Energy Transfer LP (NYSE:ET) operates. Reuters has highlighted continued investment in U.S. gas-fired generation, LNG infrastructure, and pipeline networks as electricity demand rises and countries seek reliable energy supplies. The U.S. is also building substantial additional LNG export capacity. That matters because Energy Transfer's extensive midstream network can benefit from higher volumes of natural gas, crude oil, and NGLs without taking the same direct commodity-price exposure as upstream producers. If rising power demand from data centers and continued LNG development drive greater demand for U.S. gas transportation, Energy Transfer could see expanding opportunities to place additional infrastructure into service and lock in long-duration cash flows.

#transfer #company #infrastructure #listing

Lil Durk has been cleared of every charge in the federal murder-for-hire trial that drew packed courtrooms, celebrity spectators and crowds of supporters to downtown Los Angeles.
A federal jury found the 33-year-old Chicago rapper, whose legal name is Durk Banks, not guilty on September 11 after three days of deliberations. The case centered on an August 2022 attack targeting rapper Quando Rondo that instead killed Rondo's 24-year-old cousin, Saviay'a Robinson, according to The ******* ociated Press.
Prosecutors accused Durk of financing and directing the attack in retaliation for the 2020 killing of his close friend Dayvon "King Von" Bennett. Durk's lawyers argued that former ******* istant Kavon Grant organized the plot without the rapper's knowledge and attacked the credibility of cooperating witnesses who had reached plea agreements with the government.
Durk was not released after the verdict. He remains in federal custody because he faces a separate trial involving murder-related racketeering and firearms allegations, with jury selection currently scheduled to begin October 5.
Durk had faced five counts: conspiracy to commit stalking, stalking using a dangerous weapon, stalking resulting in death, conspiracy to use interstate commerce facilities to commit murder-for-hire resulting in death and use of interstate commerce facilities to commit murder-for-hire resulting in death.

#commit #stalking

Nyxoah SA (NASDAQ:NYXH) announced the first patient implantation in BREATHE on September 7. The prospective, single-arm U.S. post-approval study will evaluate Genio hypoglossal-nerve stimulation in adults aged 22 or older with moderate to severe obstructive sleep apnea for whom standard-care treatments have failed, cannot be tolerated, or are unsuitable. Plans call for up to 229 patients at up to 25 centers, with follow-up lasting up to five years.
For Nyxoah SA (NASDAQ:NYXH), the milestone begins a new phase of evidence collection following Genio's August 2025 FDA approval. The co-primary effectiveness endpoints are apnea-hypopnea-index and oxygen-desaturation-index responder rates at 12 months. Device- and procedure-related serious adverse events will be **** sed at 12 months and annually thereafter. The investment question is whether that evidence can help turn clinical credibility into sustained commercial adoption.
Nyxoah SA (NASDAQ:NYXH) has an opportunity to demonstrate how Genio performs across different physicians and treatment settings. Consistent outcomes across participating centers could give referring sleep physicians and implanting surgeons greater confidence in patient selection and treatment delivery.
The product offers a distinct approach. Genio stimulates hypoglossal nerves on both sides of the tongue, using a battery-free implant powered by an external wearable. For Nyxoah SA (NASDAQ:NYXH), documenting effectiveness and safety in routine practice could help physicians **** s how that design fits their patients' needs.
Longer follow-up could also strengthen the evidence available to payers. Nyxoah SA (NASDAQ:NYXH) could use sustained responses and safety findings to support coverage discussions, while participating centers gain practical experience with implantation and follow-up. That would make BREATHE valuable beyond a single headline response rate.

#nyxoah #NASDAQ #nyxh

Elon Musk has slammed director Alex Gibney as a "bitter old man" with "zero integrity" after the release of Gibney's four-hour documentary about the tech mogul.
The documentary, ***** led "Musk," was billed as a "definitive and unvarnished examination" of the ***** eX boss. However, he fired back, calling it a "hit piece that misses."
Musk had already been pulled into a social media drama after his former partner, Ashley St. Clair, claimed she turned down a $40 million offer from his team in exchange for not participating in the documentary.
The outspoken billionaire launched a furious public tirade against Alex Gibney following the premiere of "Musk," an unflinching four-hour documentary examining his life, power, and global political influence at the Venice Film Festival.
Taking to X (formerly Twitter), the platform he acquired for $44 billion in 2022, the tech billionaire dismissed the documentary. He also attacked the director's personal and professional credibility, calling him a "bitter old man" who has "zero integrity."

#alex #gibney #hour

Prominent economist Mohamed El-Erian argues hyperscalers and national governments are issuing a flood of bonds to keep up their rapid spending velocity onto fewer buyers. Those straightforward circumstances are pushing bond yields up.
"If you look at the amount of issuance that's coming from governments, from hyperscalers, from companies, it far exceeds what you can count on in terms of reliable buyers, and that's why there's been pressure on interest rates, El-Erian told CNBC in an interview on Friday. "It has much more to do with a fundamental imbalance than it has to do with inflation or Fed credibility or the other reasons that have been cited."
Jeff Bezos backs a platform that lets anyone invest in rental homes for as little as $100 — 6 ways to build wealth like a landlord without actually being one
Dave Ramsey warns nearly 50% of Americans are making 1 big Social Security mistake. Here's what it is and 3 simple steps to fix it ASAP
The tax breaks in Trump's 'big beautiful bill' expire after 2028. Here are 4 moves to make before the window closes

#governments #Friday

A royal expert claims Prince Harry and Meghan Markle want the "best of both worlds" with their UK move. She alleged that they want access to the royal family while maintaining their independent lives in the US. The Sussexes arrived in the country on August 26 and are reportedly looking for private accommodation outside London.
Royal commentator Kinsey Schofield told Fox News Digital that Harry and Markle's latest move to the UK could be more about testing the waters than a permanent relocation. She said, "I suspect they want the best of both worlds — access to Britain, proximity to the monarchy and the credibility that comes with Harry's royal identity, while maintaining the freedom and commercial opportunities they ***** ociate with life outside the U.K."
The commenter added that their current arrangement seems familiar to the "half-in, half-out" policy, which Queen Elizabeth rejected when they left the UK in 2020. She further cast doubt on the Sussexes' true plan, unable to comprehend whether they are back in the country permanently or simply want the experience of the "best of both worlds."
"Harry and Meghan never do what they say or say what they mean. One year ago, Harry told us the U.K. was not safe enough to bring his wife and children. Now someone is briefing the Daily Mail that Harry has a 15-year plan in the U.K. Alternatively, we're briefed this could be temporary," she elaborated. Schofield described their current arrangement as a trial rather than a permanent homecoming.
Recently, another royal commentator, Lady Colin Campbell, shared an update on whether the royal family would accept the Sussexes, now that they're back. She said, "The family wants absolutely nothing to do with her and as little to do with Harry as possible." She also stated that people who want to remain in the good books of the Waleses and the monarch would be unlikely to ***** ociate themselves with the Sussexes.

#harry

Startups spend years courting brand-name investors to build credibility before they go public. Rarely does one of those investors also happen to be the company's biggest supplier, and in a roundabout way, one of its own paying customers.
Nscale, a two-year-old British AI cloud computing firm, is negotiating to raise up to $3.5 billion ahead of a planned U.S. stock listing, according to Bloomberg.
Nvidia (NVDA) is expected to supply about $2 billion of that financing, with hedge fund Third Point leading a separate tranche of convertible notes and Goldman Sachs running the process.
The arrangement would make Nscale's chip supplier one of its largest shareholders just weeks before the company asks public investors to back a valuation roughly double its last private round.
Related: Nvidia stock flashes unusual signal for investors

#investors #public #rarely

Prominent economist Mohamed El-Erian argues hyperscalers and national governments are issuing a flood of bonds to keep up their rapid spending velocity onto fewer buyers. Those straightforward circumstances are pushing bond yields up.
"If you look at the amount of issuance that's coming from governments, from hyperscalers, from companies, it far exceeds what you can count on in terms of reliable buyers, and that's why there's been pressure on interest rates, El-Erian told CNBC in an interview on Friday. "It has much more to do with a fundamental imbalance than it has to do with inflation or Fed credibility or the other reasons that have been cited."
Jeff Bezos backs a platform that lets anyone invest in rental homes for as little as $100 — 6 ways to build wealth like a landlord without actually being one
Dave Ramsey warns nearly 50% of Americans are making 1 big Social Security mistake. Here's what it is and 3 simple steps to fix it ASAP
The tax breaks in Trump's 'big beautiful bill' expire after 2028. Here are 4 moves to make before the window closes

#governments #buyers #jeff #bezos

Wall Street sees a blowout jobs report and spiking Treasury yields as another sign that the Fed is going to have to hike rates to clamp down on inflation.
The US economy added 162,000 jobs last month, blowing past economists' expectations. If the Fed was looking for clues of a slowing economy, this report wasn't it.
"They're a little bit behind the curve," Joe Brusuelas, RSM chief economist, told Yahoo Finance, in reference to the central bank. "They're going to need to hike rates if they want to reinforce their credibility, and that's going to cause a lot of problems at 1600 Pennsylvania Avenue."
The Trump administration has been pushing hard for lower rates to bring borrowing costs down and flatten the yield curve, with the president threatening a trade embargo if they don't.
Read more: How jobs, inflation, and the Fed are all related

#Jobs #rates #curve

Wall Street sees a blowout jobs report and spiking Treasury yields as another sign that the Fed is going to have to hike rates to clamp down on inflation.
The US economy added 162,000 jobs last month, blowing past economists' expectations. If the Fed was looking for clues of a slowing economy, this report wasn't it.
"They're a little bit behind the curve," Joe Brusuelas, RSM chief economist, told Yahoo Finance, in reference to the central bank. "They're going to need to hike rates if they want to reinforce their credibility, and that's going to cause a lot of problems at 1600 Pennsylvania Avenue."
The Trump administration has been pushing hard for lower rates to bring borrowing costs down and flatten the yield curve, with the president threatening a trade embargo if they don't.
Read more: How jobs, inflation, and the Fed are all related

#hike

OTTAWA, Sept 3 (Reuters) - Canadian Prime Minister Mark Carney said on Thursday his government was ready to sign a trade deal ‌with the U.S. that benefits both countries, adding any agreement would ‌need to have stability and credibility.
"The deal that's possible, that's in the interests of Canadian workers, families and businesses, is also the deal that is in the interests of American families, American businesses, American consumers, and ... we're ready to sit down and strike that deal when the Americans are ready," Carney told reporters ‌in Thunder Bay, Ontario.
Carney ⁠dismissed recent comments by U.S. Commerce Secretary Howard Lutnick and Treasury Secretary Scott Bessent that Canada walked away from a ⁠trade deal because of domestic politics, saying in response to a question, "I don't think, with all respect, appointed, unelected cabinet members in the United States are experts on Canadian politics."
Carney suggested there had been a recent softening in the ‌U.S. approach to any trade deal that could spur further discussions.
"There were a few issues that the United States was arguing right up to the last hour," he said, describing it as an "our way or the highway" attitude before talks broke down last month. "Now, they're not," he said. "So all of ‌a sudden, they don't care about Canadian language or culture and those elements. Well, if they didn't care, they shouldn't have kept them in the deal," Carney said. "It's good. ‌We welcome that."

#carney #canadian #ready #interests

ACCRA, Ghana (AP) — Carlos Queiroz is back as coach of Ghana less than two months after quitting the role following World Cup elimination in the last 32.
Queiroz held fresh talks with the Ghana Football ****** ociation and the country's Ministry of Sports and Recreation, after which the Portuguese coach was handed another contract in charge.
The GFA said in a statement late Wednesday that it "believes Queiroz's extensive international experience, technical expertise and knowledge of the Black Stars position him strongly to lead the team into this new chapter."
The 73-year-old Queiroz, who has coached Portugal, Colombia, Iran and Egypt at international level and Real Madrid at club level, left as Ghana coach after a 1-0 loss to Colombia at the first knockout stage.
He said there was no "complete sporting satisfaction" but felt the team brought "respect and credibility to the Black Stars."

#team

Ferguson expects two rate hikes before early next year, warning five years of missed inflation targets threaten the Fed's credibility.
Ferguson dismisses Warsh's balance sheet hints as ineffective and warns Treasury interference is distorting the bond market signals guiding policy.
Consumer sentiment sits at 49.5, below the 60 recessionary threshold, making Ferguson the hawkish outlier against El-Erian and JPMorgan expecting dovish guidance.
Don't wait: the ******* yst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.
Former Federal Reserve Vice Chairman Roger Ferguson expects two interest rate hikes across the rest of 2026 and early 2027, warning that persistent inflation could damage the central bank's credibility if officials fail to act. His forecast is more hawkish than those of observers expecting only one increase.

#hikes #credibility

Peyton Watson is widely regarded as one of the most promising young wings in the NBA. Although this year's offseason was marked by prolonged contract talks and the inevitable drama that follows, Watson now finds himself in a new environment after being traded to the Cleveland Cavaliers.
While joining the Cavs could be a phenomenal opportunity for Peyton Watson, it is worth acknowledging his time spent with the Denver Nuggets. Having established himself as an elite two-way player over the 2025-26 season, Watson's credibility as a versatile defender undoubtedly boosted his overall stock.
Because of his ability to guard multiple positions, Peyton Watson has often faced some of the league's best offensive players. Thus, when asked who he considered the toughest player to guard on a recent episode of the "Curious Mike" podcast with Michael Porter Jr., Watson had to give a shout-out to one of the league's most creative scorers.
"Definitely, Kyrie Irving is on top of that list," Watson stated. "Bro, because you can literally just play perfect defense and he's just a basketball savant. He's got the most sophisticated and most refined game that I feel like I've ever seen."
"That's one of those guys that you look at and say, and I use this all the time, but the best of the best, bro, their talent is in their fingertips," Watson continued. "It's like he touches that ball, and he's just like a painter with an open canvas, and they're just out there playing like it's art, and Kyrie's one of those guys. Super tough to guard."

#peyton #time

Tempus AI, Inc. (NASDAQ:TEM) rallied following a melanoma breakthrough reported by Moderna and Merck. The companies said their Phase 3 INTerpath-001 trial met its recurrence-free survival endpoint for the personalized cancer therapy intismeran autogene, also known as V940, combined with Keytruda. Detailed trial data remain pending. The read-through came from Personalis, which has supported the V940 clinical-development program since its inception. Tempus agreed in July to a pending acquisition of Personalis at a $1.5 billion enterprise value, net of Tempus's existing stake. The question for Tempus AI, Inc. (NASDAQ:TEM) is whether the result validates the acquisition or merely confirms that one Personalis platform is strategically relevant to personalized cancer therapy.
Personalis uses ImmunoID NeXT to sequence tumor information for personalized vaccine development. That technology is distinct from NeXT Personal, the company's tumor-informed molecular residual disease test and the central strategic target of the acquisition. For Tempus AI, Inc. (NASDAQ:TEM), the clinical result validates Personalis's sequencing capabilities without establishing the economics of either product.
Tempus AI, Inc. (NASDAQ:TEM) is acquiring a company that has supported the V940 program from its beginning. A successful Phase 3 endpoint could strengthen Personalis's credibility with biopharma customers and create additional sequencing opportunities as drugmakers pursue individualized therapies across more tumor types.
The acquisition also reaches beyond vaccine sequencing. Tempus AI, Inc. (NASDAQ:TEM) has commercialized NeXT Personal since 2023. The MRD test searches for small traces of circulating tumor DNA after treatment, helping clinicians monitor response and identify possible recurrence before it becomes visible through conventional imaging.
Tempus AI, Inc. (NASDAQ:TEM) reported 9,000 total MRD tests in the second quarter, up from 6,500 sequentially. Personalis generated finalized quarterly revenue of $22.357 million and delivered 10,384 clinical tests, with volume rising 33% sequentially. NeXT Personal also has Medicare coverage in three indications, giving the pending transaction a commercial foundation independent of V940.

#v940 #acquisition #tumor

The stock market saw solid gains for the major indexes, rebounding off their 21-day moving averages, though small caps fell slightly toward their 50-day line. Federal Reserve Chairman Kevin Warsh leaned hawkish in his Jackson Hole speech, and markets generally seemed to like it. Nvidia (NVDA) surged on booming earnings and blowout guidance, but many chip and AI hardware plays struggled. Negative earnings reactions to Marvell (MRVL) and Everpure (P) didn't help. Meanwhile, Salesforce (CRM), CrowdStrike (CRWD), Okta (OKTA) and Elastic (ESTC) were big software earnings winners, fueling a bisector move. Youth apparel retailer Abercrombie & Fitch (ANF) skyrocketed while ****** 's Sporting Goods (DKS) dived.
The major indexes rose solidly off their 21-day moving averages, not far from record highs, though small caps retreated toward their 50-day line. Fed Chief Kevin Warsh's Jackson Hole speech got a generally positive reaction. Nvidia (NVDA), Salesforce (CRM), CrowdStrike (CRWD), Okta (OKTA), Elastic (ESTC) and Abercrombie & Fitch (ANF) were among the notable earnings winners. Crude oil prices and the 10-year Treasury yield fell, though they came off weekly lows.
Federal Reserve Chairman Kevin Warsh, coming off his July 29 news conference that left Wall Street doubting his inflation-fighting credibility, turned the page with Friday's address at the annual Jackson Hole, Wyo., monetary policy conference. Warsh said his perception is that the economy has strengthened, allowing the Fed to focus on achieving its 2% inflation target. Citing strong business capital spending and strong profit growth, with the exceptions of housing and agriculture, Warsh said he would be "hard pressed to describe broad financial conditions as restrictive." Reaction to his address lifted odds of a Sept. 16 Fed rate hike to 56% from around 35% on Thursday, according to CME Group's FedWatch tool.
The latest inflation data may have added to pressure on Fed Chair Warsh to set a hawkish tone on Friday. The PCE (personal consumption expenditures) price index topped forecasts with a 0.2% rise that kept the 12-month headline inflation rate at 3.7%. Core inflation held at 3.3%, though the figure was 3.344% when unrounded to the nearest tenth of a percent. Q2 GDP growth was unrevised at an unimpressive 1.5%, but the underlying measure of growth was revised to a sizzling 4.2% from 3.9% initially. That reflects final real sales to private domestic purchasers. The Bureau of Labor Statistics said it expects to revise payroll growth in the year through March down by 79,000 overall and 178,000 for the private sector. That would leave 12-month gains of 195,000 overall and 321,000 for private employers.
AI chip leader Nvidia (NVDA) posted a beat-and-raise fiscal second-quarter report and gave a bullish forecast for next year. Nvidia stock jumped on the news. Adjusted earnings surged 112% year over year. Sales soared 106% to $96.2 billion, the fourth straight quarter of accelerating revenue g

On August 20, 2026, Micron Technology, Inc. (NASDAQ:MU) CEO Sanjay Mehrotra said artificial intelligence has fundamentally altered the memory industry's historically volatile boom-and-bust cycle, telling CNBC's "Mad Money" that "today there is no AI without memory."
Mehrotra said data-center customers currently want roughly 50% more supply than Micron can commit to delivering. The firm has signed five-year strategic agreements with more than 16 customers to lock in demand, up from the number disclosed on its late-June earnings call. Micron is backing that outlook with a planned $250 billion investment in U.S. manufacturing through 2035, including two new fabs in Boise, Idaho. It separately unveiled a $10 billion Micron Research Labs initiative, endorsed by Nvidia CEO Jensen Huang and Apple CEO Tim Cook.
Demand is running well ahead of what Micron Technology, Inc. (NASDAQ:MU) can physically supply. Data-center customers want about 50% more memory than Micron can commit to, a supply-demand gap severe enough that all its customers across our end markets will buy everything that it makes. That kind of shortage, rather than oversupply, is the opposite of the environment that has historically crushed memory prices.
Long-term contracts are replacing the spot-market exposure that drove past boom-bust cycles. Micron has signed five-year strategic agreements with more than 16 customers who have "committed to taking the supply." It gives Micron real visibility into future demand instead of relying on volatile spot pricing that has wrecked memory margins in past cycles.
Micron is backing its confidence with capital, not just commentary. The firm's $250 billion U.S. manufacturing commitment through 2035, plus a separate $10 billion Micron Research Labs investment, signals a multi-decade bet on sustained AI-driven demand. The research initiative's endorsement from customers as significant as Nvidia and Apple lends outside credibility to that bet.

#memory #supply #Research #technology

Phillip Securities ****** yst Glenn Thum recently set a target price of $75 per share for ****** e Exploration Technologies (NASDAQ: SPCX). As of the time of this writing, that would amount to a 45% decline in the stock price. Moreover, Thum has a five-star rating on TipRanks and an 87% success rate, which has won him considerable credibility.
Admittedly, only two out of 35 ****** ysts rate ****** eX as a sell, and certainly, such forecasts do not always come to pass. Nonetheless, it highlights some risks with owning ****** eX stock.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Here's why investors would probably serve themselves well by heeding this warning.
Thum pointed out a few reasons for his negative outlook on this company. He noted its capital expenditures (capex), which now amount to approximately 2.4 times ****** eX's revenue in the second quarter of 2026. Additionally, Thum expressed some discomfort with 19.5% of Q2 group revenues coming from a single AI customer, widely believed to be Anthropic.

#thum #Stock

With the focus of global investors shifting away from the short-term economy to long-term fiscal credibility, the US dollar started its day on August 24 on multi-month lows. Although Treasury Department's plan to double buybacks to the tune of $4 billion per operation on 10- to 30-year debt has eased concerns in some market circles, others are concerned that Washington intends to further suppress long-term borrowing via the deficit without remediation. U.S. 30-year yields are at 5.337%, last week's 19-year highs, and a slightly better than expected Services report on Friday did little to push the dollar higher. Investors are watching both Friday's speech by Fed Chair Kevin Warsh from Jackson Hole and July's inflation for more insight on the possible direction and duration of monetary policy.
Buyer perception is that the ECB will continue to adhere to the fight against inflation after the September opening of a 2.5% deposit rate. In the meantime, while the recovery in Europe is uneven, sentiment in the markets is that recent growth data and business activity support the push for further inflation focus against the backdrop of the Iran conflict.
Sterling is further supported by the comparative relationship with the dollar. Fed Chair Kevin Warsh rose to 2.9% in July, while second-quarter GDP increased by 0.4%. There were also declines in retail sales and an unexpected budget deficit by the government which has weakened prospects. With all of this in mind, the best case scenario is still limited. Most economists predict interest rates will stay the same for the remainder of 2022. That said, inflation is still expected to rise enough to prompt the Bank of England for at least one interest rate hike in 2026.
For August 24, the primary FX theme is increased uncertainty over U.S. fiscal policy and treated the dollar as being weak, while the risks of tightening by the ECB and BoE supported the euro and pound.
For the U.S. Dollar Index, the 4-hour chart shows a price currently at $98.89 after breaking the $99.38 support. The price is below the 50, and 100, period Exponential Moving Averages (EMAs) confirming a bearish sentiment. The price has been attempting to stabilize in the range of $98.55 to $98.82, and has broken some support, but no major resistances have been established.

#inflation #support #price #kevin

Three of the biggest names in logic chips closed higher on August 12, following a strong earnings report deep in the AI server supply chain. Advanced Micro Devices, Inc. (NASDAQ:AMD) up 1.8% at $483, Intel Corporation (NASDAQ:INTC) up 3.3% to $101, and NVIDIA Corporation (NASDAQ:NVDA) up 3% to $224, in a broad rally sparked not by news from any of the three companies, but by Super Micro Computer Inc. (NASDAQ:SMCI), whose results reinforced how strong AI infrastructure expenditure remains.
On August 11, Super Micro Computer Inc. (NASDAQ:SMCI) released its fiscal fourth-quarter report, and the results were impressive on two fronts. Non-GAAP earnings per share came in at $1.70, up 139% from the roughly $0.71 ******* ysts projected, though revenue of $11.12 billion fell just short of expectations. The major story, however, was the order book: Super Micro reported more than $60 billion in new orders received during the quarter alone, up more than 50% compared to the $39 billion the company reported just six weeks prior.
The margin story was equally as important as order growth. Super Micro's non-GAAP gross margin increased to 17.6%, more than doubling the previously forecast 8.2%-8.4% range, which management put down to a better mix of customers and products.
That's why the rise extended far beyond Super Micro's own shares. For NVIDIA Corporation (NASDAQ:NVDA), whose GPUs power the servers Super Micro builds, the order surge acts as an independent data point confirming that demand for its chips continues to be strong ahead of its own upcoming fiscal second-quarter report, which includes revenue projections of roughly $91 billion excluding China data-center compute. NVIDIA enters that report up 19.23% year-to-date, has a $80 billion share buyback authorization, and recently announced a $500 billion financing arrangement with a broad collection of Wall Street banks.
Advanced Micro Devices, Inc. (NASDAQ:AMD), which is up a staggering 130.08% year to date, has its own reasons to gain something from the read-through. The company has been securing major GPU deployment orders, including contracts for up to 2 gigawatts of its MI450 accelerators for Anthropic, establishing itself as the most credible competitor to NVIDIA in AI data center silicon. A robust server-supply-chain signal, such as Super Micro's, lends credibility to the broader notion that there is enough demand for AI infrastructure to support several chip suppliers.

#report #strong

LONDON (AP) — A British sociologist who resigned last week from the University of Cambridge following weeks of public accusations of plagiarism and media scrutiny was found dead Friday.
Jason Arday, who was 37 when he became Cambridge's youngest Black professor in 2023, resigned after he came under intense media pressure, with weeks of allegations about plagiarism in his academic work and questions surrounding claims about his athletic and fundraising accomplishments.
The Times and Telegraph newspapers, along with the BBC and Sky News, reported that Arday, 41, was found "unresponsive" inside a home in Battersea, south London, on Friday afternoon.
News of his death comes the same week as the release of his memoir, "Great and Unfortunate Things," a highly anticipated work that Simon & Schuster had decided to release despite the doubts about his credibility. In a statement issued through his publisher, Arday's family said that they were "in shock to have lost this amazing father, partner, brother, uncle and son."
"The campaign of misinformation was too much for Jason, who was a gentle man and who always wanted to see the best in everyone," the family said, adding that for three years Arday was "subjected to a campaign of sustained abuse ... by those who would leave no stone unturned in their quest to undermine him."

#arday #london #Friday #weeks

Honeywell Aerospace Inc. (NASDAQ:HONA) is the aerospace spinoff of former conglomerate Honeywell International. With Cramer having openly admitted that he has a bias for aerospace stocks, it wasn't unsurprising that he was one of the spinoff's biggest supporters before it occurred. While most of his attention was focused on the firm's quantum computing spinoff, he nevertheless defended the conglomerate after multiple less-than-stellar earnings reports. However, as Honeywell Aerospace Inc. (NASDAQ:HONA)'s dropped on August 6th, here's what Cramer said in the morning:
"Let me talk about Honeywell Aerospace, because we owned Honeywell and we got some of this. And we sold it. And we sold it because, not because the company missed. But I think the company missed because they were hopeful. There were multiple opportunities to let shareholders know that there were supply chain problems that would cause them to miss the quarter. They waited, and waited, and waited, and didn't tell us until they reported. I think that was ill-advised, an ill-advised way to disseminate the information.
"The problems at Honeywell were actually systemic. They were really, really bad. There were many suppliers, even though it was just a couple of small percent. The cut was so big that the credibility of the company is in question. . .I spoke with management, it's funny Carl, I spoke with management. . .there would have been a time. . .where people would have said, oh my god, this is terrible. It was not dishonesty, it just was new. It was a rookie mistake. . .they should have realized, look we're just being hopeful. . .suboptimal way to report. . ."
Later, Cramer added that he would have preferred a preannouncement like IBM. The results that he was talking about were Honeywell Aerospace Inc. (NASDAQ:HONA)'s second quarter earnings report released on the 5th. It saw Honeywell Aerospace Inc. (NASDAQ:HONA) miss ******* yst revenue and earnings estimates. More importantly, the firm also lowered full year 2026 organic sales growth forecast to 4% to 5% from an earlier 7% to 9%.
Naturally, with the earnings being the first since the spinoff, they also point towards bullish and bearish viewpoints for Honeywell Aerospace Inc. (NASDAQ:HONA). On the bearish front, the firm's supply chain weaknesses were thrown into the spotlight. CEO Jim Currier admitted that the supply chain had been unable to ramp according to expectations, but added that Honeywell Aerospace Inc. (NASDAQ:HONA) was making progress with initiatives to "integrate supplier capacity, factory operations and customer delivery to create predictable growing throughput." The firm's CFO Joshua Jepsen admitted that in order to meet the spares market's capacity, Honeywell Aerospace Inc. (NASDAQ:HONA)'s investments would " dampen near-term financial performance in the back half."

#cramer

Recent public comments from lifestyle icon Martha Stewart have reportedly sparked a feud between her and the ***** ss of Sussex, Meghan Markle.
The celebrity chef publicly called out Meghan's transition from actress to royalty, then to lifestyle entrepreneur, taking a swipe at her new brand and credibility as a televised "homemaking guru."
According to a new report, Meghan Markle was left upset by the candid remarks and Martha Stewart's claims that she talked about her recent royal family reunion in the UK.
¡dehoy! Agency / MEGA
The 85-year-old lifestyle veteran critiqued Meghan's career transitions in an interview with People Magazine.

#recent

Fleet safety directors spend years building compliance programs that ****** ody ever asks them to defend out loud, and when someone finally does, it is a plaintiff's attorney with a court reporter in the room. Trucksafe Consulting is selling the rehearsal.
The DOT compliance consultancy will hold its fifth annual Fleet Compliance Bootcamp Sept. 16-17, 2026, at the Crowne Plaza Indianapolis-Downtown-Union Station, and this year's program adds a half-day Live Deposition Simulation and Rule 30(b)(6) Preparation Seminar on Sept. 18.
Trucking deposition preparation usually begins after a lawsuit is filed, which is also the point at which the record stops being fixable. Attendees will watch a realistic deposition of a fleet safety director in a serious highway-accident case. Plaintiff and defense attorneys will demonstrate the questioning strategies, document issues and credibility challenges they use in live cases. A panel discussion afterward will examine how testimony and company records affect liability exposure and settlement value.
"Today, a compliance failure rarely stays confined to an enforcement proceeding," said Brandon Wiseman, president and founder of Trucksafe Consulting. "After a serious accident, attorneys will scrutinize years of driver files, maintenance records, safety data, policies, emails and management decisions."
The exposure is retroactive, and it reaches documents ****** ody wrote expecting an audience.

#fleet

Procter & Gamble (NYSE:PG) is buying its way into wellness. On August 4, L Catterton announced it had signed a definitive agreement to sell Thorne, a science-backed health and wellness brand, to Procter & Gamble for $3.8 billion in cash. The deal lands a day after an August 3 ****** ysis flagged a fiscal 2027 earnings guide that came in below expectations, weighed down by roughly $1 billion in new cost headwinds. Investors now have two stories to weigh at once: fresh expansion and a tougher near-term cost picture.
The Thorne acquisition gives Procter & Gamble entry into a category built on clinical credibility rather than shelf ****** e. Thorne has spent 40 years building relationships with healthcare practitioners, and L Catterton's announcement noted the company developed a proprietary AI wellness advisor to help consumers navigate its supplement lineup, a tool practitioners can point their patients to directly.
The transaction is expected to close in the fourth quarter of 2026, an all-cash deal with no debt or equity swapped into the mix. Procter & Gamble isn't skimping on shareholders while it shops, either. The company returned $10.2 billion in dividends and $5.0 billion in share repurchases during fiscal 2026, and it plans roughly the same combination, about $10 billion in dividends and $5 billion in buybacks, for fiscal 2027. There's a case buried inside the company's own guidance, too. Strip out the roughly $1 billion in commodity, energy, and transportation costs management expects to absorb next year, and core EPS would be growing at about 10% instead of the 0% to 3% baked into the outlook.
The numbers behind the fiscal 2027 outlook explain the caution. Management guided core EPS to $6.89 to $7.11, implying growth of just 0% to 3%, and pointed to roughly $1 billion in after-tax commodity, energy, and transportation costs as the main culprit. Add higher net interest expense, lower non-operating income, and unfavorable currency, and the total drag reaches $0.56 per share, wiping out about 8 percentage points of core earnings growth before the year even starts.
The trend already shows up in recent results. In the fiscal fourth quarter, net sales rose 2% year-over-year to $21.2 billion while organic sales were flat, and core EPS fell 3% to $1.43. For the full fiscal year, net sales grew 3% to $87.0 billion, but organic sales rose only 1%, and every bit of that growth came from higher prices rather than more units sold. Volume and mix didn't move. Shares trade near $144, about 5% above their 52-week low of $137.62, or roughly 21 times fiscal 2026 core earnings of $6.89. That's not an expensive multiple, but it isn't cheap for a business guiding to low-single-digit growth.

#gamble #thorne

Martha Stewart believes her five-month prison sentence added an unexpected element to her carefully cultivated public image. More than two decades after serving time in connection with a stock-trading scandal, the lifestyle mogul reflected on the experience and insisted that being incarcerated gave her "street cred." However, Martha Stewart also rejected the comparatively comfortable reputation of the minimum-security federal facility where she completed her sentence, describing it as "a horrible place."
MPI099/Capital Pictures / MEGA
Stewart served her sentence at Federal Prison Camp Alderson in West Virginia between October 2004 and March 2005. During a new interview with PEOPLE, she acknowledged how the experience affected the way the public viewed her. "Of course it gave me street cred," Stewart said. "I mean, you would never know what jail was like until you go to jail."
When the interviewer suggested that her newfound credibility may have helped bring her closer to longtime friend Snoop Dogg, Stewart rejected the theory and explained that their connection began with her interest in hip-hop.
"No, I don't think Snoop likes me because I have street cred. I invited Snoop to be on my show [in 2008] because he was a rapper, and I was attracted to rappers. I like rap music. I especially like Eminem, and I could never get Eminem to come on any show. He would not accept any invitation. I still haven't met him," she said.

#prison

Christopher Vizzina has waited three years for an opportunity to become Clemson football's starting quarterback. As fall camp gets underway, the senior is closer than ever to getting his shot.
Dabo Swinney confirmed Thursday that Vizzina remains ahead of freshman Tait Reynolds in the race to replace Cade Klubnik, who was selected by the New York Jets in the fourth round of the NFL draft.
"Again, he's got the pole position, but he's still gotta finish the race," Swinney said.
"He's gotta go finish the race, but he's got a lead into the second half here, so we'll see what happens."
Vizzina hasn't played much during his Clemson career, but he has spent those years developing behind Klubnik rather than looking elsewhere for an easier path to playing time. Swinney believes that approach has helped Vizzina earn credibility inside the Tigers' locker room.

#race #klubnik #finish #christopher